MedImmune is the global biologics R&D arm of AstraZeneca
MedImmune is committed to scientific innovation and medical progress, continually looking beyond standard expectations and pushing the boundaries of what is possible.
MedImmune has been shaping biotechnology innovation for nearly three decades, leading the industry in antibody drug development through core technologies that include hybridoma and phage display. We’ve also mastered optimisation to improve the safety and potency of antibody leads. We anticipate the future; we follow the science that translates into successful antibody therapeutics.
MedImmune’s Cambridge site is the company’s European hub and, with its historical foundations in Cambridge Antibody Technology (acquired by AstraZeneca in 2006, and integrated with MedImmune in 2007), perfectly complements MedImmune’s US headquarters in Gaithersburg, Maryland.
The MedImmune Cambridge team contributes to all the therapy areas of interest to MedImmune, and works in integrated project teams with colleagues in Gaithersburg and California. In particular, MedImmune Cambridge is recognised for its excellence in the following areas of R&D activity:
- Antibody Discovery and Protein Engineering:
- Display technologies (phage display, ribosome display)
- Protein sciences, molecular biology
- High throughput screening, biochemical assays and automation
- Integrated data tracking and analysis
- Knowledge management
- Disease understanding:
- Therapeutic area-specific biology
- Cell biology
- Translational science
- Biopharmaceutical development:
- Cell-line production
- Downstream processing
- Analytical biochemistry
- Clinical development
- Project management
- Legal, intellectual property
- Regulatory affairs
To achieve its aims of delivering real benefits to patients, MedImmune recognises the need to look beyond its own research activities; seeking out and working with the best scientists, experts and medical professionals. We are therefore committed to working with external collaborators and partners around the world at all stages of our R&D activities. Embracing this philosophy, MedImmune Cambridge has strong collaborative links with academics, researchers, charities, foundations and companies – locally, regionally, nationally and globally.
MedImmune is the global biologics research and development arm of AstraZeneca and is pioneering innovative research and exploring novel pathways across key therapeutic areas, including oncology; respiratory; and cardiovascular and metabolic disease.